Ampio pharmaceuticals details early positive results for inhaled ampion in covid-19 respiratory distress

Englewood, colo., march 16, 2021 /prnewswire/ -- ampio pharmaceuticals (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, recently revealed preliminary positive results in its ap-014 phase i clinical trial utilizing inhaled ampion in treating respiratory distress in patients as a result of covid-19.
AMPE Ratings Summary
AMPE Quant Ranking